David Weiner

David has over 20 years of experience in the discovery and clinical development of novel therapeutics for neurological disease. David started his career at ACADIA Pharmaceuticals, where, over a ten-year period, he held a series of discovery research and clinical development roles working on multiple CNS therapeutics, most notably Nuplazid/Pimavanserin, a serotonin 5-HT2A inverse agonist recently approved for the treatment of Parkinson’s Disease related psychosis. David formerly led EMD Serono’s global early clinical development activities in neurology and has extensive experience in rare disease drug development, having served as CMO and Interim CEO for Proteostasis Therapeutics Inc., and most recently as CMO at Lumos Pharma.

David received his MD from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, and was a Howard Hughes Medical Institute Research Scholar at the National Institute of Health in Bethesda.